The skin serves as the foremost barrier between the internal body and the external world, providing crucial protection against pathogens and chemical, mechanical, and ultraviolet damages. The skin is a central player in the intricate network of immune, neurologic, and endocrine systems. The endocannabinoid system (ECS) includes an extensive network of bioactive lipid mediators and their receptors, functions to modulate appetite, pain, mood, and memory, and has recently been implicated in skin homeostasis. Disruption of ECS homeostasis is implicated in the pathogenesis of several prevalent skin conditions. In this review, we highlight the role of endocannabinoids in maintaining skin health and homeostasis and discuss evidence on the role of ECS in several eczematous dermatoses including atopic dermatitis, asteatotic eczema, irritant contact dermatitis, allergic contact dermatitis, and chronic pruritus. The compilation of evidence may spark directions for future investigations on how the ECS may be a therapeutic target for dermatologic conditions.
Get full access to this article
View all access options for this article.
References
1.
RoostermanD, GoergeT, SchneiderSW, et al. Neuronal control of skin function: the skin as a neuroimmunoendocrine organ. Physiol Rev, 2006; 86(4):1309–1379.
2.
LugerTA. Neuromediators—a crucial component of the skin immune system. J Dermatol Sci, 2002; 30(2):87–93.
3.
KramerJL. Medical marijuana for cancer. CA Cancer J Clin, 2015; 65(2):109–122.
4.
BadowskiME, PerezSE. Clinical utility of dronabinol in the treatment of weight loss associated with HIV and AIDS. HIV AIDS (Auckl), 2016; 8:37–45.
5.
DavisMP. Cannabinoids for symptom management and cancer therapy: the evidence. J Natl Compr Canc Netw, 2016; 14(7):915–922.
6.
BlumenthalDE, MalemudCJ. Recent strategies for drug development in fibromyalgia syndrome. Expert Rev Neurother, 2016; 16(12):1407–1411.
7.
PatakyZ, GasteygerC, ZieglerO, et al.Efficacy of rimonabant in obese patients with binge eating disorder. Exp Clin Endocrinol Diabetes, 2013; 121(1):20–26.
8.
BiroT, TothBI, HaskoG, et al. The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities. Trends Pharmacol Sci, 2009; 30(8):411–420.
9.
KendallAC, NicolaouA. Bioactive lipid mediators in skin inflammation and immunity. Prog Lipid Res, 2013; 52(1):141–164.
10.
StanderS, SchmelzM, MetzeD, et al. Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J Dermatol Sci, 2005; 38(3):177–188.
11.
KarsakM, GaffalE, DateR, et al.Attenuation of allergic contact dermatitis through the endocannabinoid system. Science, 2007; 316(5830):1494–1497.
12.
TelekA, BiroT, BodoE, et al.Inhibition of human hair follicle growth by endo- and exocannabinoids. FASEB J, 2007; 21(13):3534–3541.
13.
DobrosiN, TothBI, NagyG, et al.Endocannabinoids enhance lipid synthesis and apoptosis of human sebocytes via cannabinoid receptor-2-mediated signaling. FASEB J, 2008; 22(10):3685–3695.
14.
AkermanS, KaubeH, GoadsbyPJ. Anandamide acts as a vasodilator of dural blood vessels in vivo by activating TRPV1 receptors. Br J Pharmacol, 2004; 142(8):1354–1360.
15.
CaterinaMJ, LefflerA, MalmbergAB, et al.Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science, 2000; 288(5464):306–313.
16.
SouthallMD, LiT, GharibovaLS, et al.Activation of epidermal vanilloid receptor-1 induces release of proinflammatory mediators in human keratinocytes. J Pharmacol Exp Ther, 2003; 304(1):217–222.
17.
VelascoG, SanchezC, GuzmanM. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer, 2012; 12(6):436–444.
18.
SmartD, JonssonKO, VandevoordeS, et al ‘Entourage’ effects of N-acyl ethanolamines at human vanilloid receptors. Comparison of effects upon anandamide-induced vanilloid receptor activation and upon anandamide metabolism. Br J Pharmacol, 2002; 136(3):452–458.
19.
De PetrocellisL, DavisJB, Di MarzoV. Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors. FEBS Lett, 2001; 506(3):253–256.
20.
CravattBF, GiangDK, MayfieldSP, et al.Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature, 1996; 384(6604):83–87.
21.
DinhTP, CarpenterD, LeslieFM, et al.Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci U S A, 2002; 99(16):10819–10824.
22.
UedaN, TsuboiK, UyamaT. N-acylethanolamine metabolism with special reference to N-acylethanolamine-hydrolyzing acid amidase (NAAA). Prog Lipid Res, 2010; 49(4):299–315.
23.
PetrosinoS, IuvoneT, Di MarzoV. N-palmitoyl-ethanolamine: biochemistry and new therapeutic opportunities. Biochimie, 2010; 92(6):724–727.
24.
WeiBQ, MikkelsenTS, McKinneyMK, et al.A second fatty acid amide hydrolase with variable distribution among placental mammals. J Biol Chem, 2006; 281(48):36569–36578.
25.
MechoulamR, DeutschDG. Toward an anandamide transporter. Proc Natl Acad Sci U S A, 2005; 102(49):17541–17542.
26.
EberleinB, EickeC, ReinhardtHW, et al. Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). J Eur Acad Dermatol Venereol, 2008; 22(1):73–82.
27.
YuanC, WangXM, GuichardA, et al. N-palmitoylethanolamine and N-acetylethanolamine are effective in asteatotic eczema: results of a randomized, double-blind, controlled study in 60 patients. Clin Interv Aging, 2014; 9:1163–1169.
28.
Del RossoJQ. Use of a palmitoylethanolamide containing nonsteroidal cream for treating atopic dermatitis: impact on the duration of response and time between flares. Cosmet Dermatol, 2007; 20(4):208–211.
29.
PulvirentiN, NascaMR, MicaliG. Topical adelmidrol 2% emulsion, a novel aliamide, in the treatment of mild atopic dermatitis in pediatric subjects: a pilot study. Acta Dermatovenerol Croat, 2007; 15(2):80–83.
30.
DvorakM, WatkinsonA, McGloneF, et al.Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin. Inflamm Res, 2003; 52(6):238–245.
31.
StanderS, ReinhardtHW, LugerTA. Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus [in German]. Hautarzt, 2006; 57(9):801–807.
32.
SzepietowskiJC, SzepietowskiT, ReichA. Efficacy and tolerance of the cream containing structured physiological lipids with endocannabinoids in the treatment of uremic pruritus: a preliminary study. Acta Dermatovenerol Croat, 2005; 13(2):97–103.
33.
PetrosinoS, CristinoL, KarsakM, et al.Protective role of palmitoylethanolamide in contact allergic dermatitis. Allergy, 2010; 65(6):698–711.
34.
OkaS, WakuiJ, IkedaS, et al.Involvement of the cannabinoid CB2 receptor and its endogenous ligand 2-arachidonoylglycerol in oxazolone-induced contact dermatitis in mice. J Immunol, 2006; 177(12):8796–8805.
35.
CorkMJ, DanbyS. Skin barrier breakdown: a renaissance in emollient therapy. Br J Nurs, 2009; 18(14): 872, 874, 876–877.
36.
LodenM. Effect of moisturizers on epidermal barrier function. Clin Dermatol, 2012; 30(3):286–296.
37.
PalattyPL, AzmidahA, RaoS, et al.Topical application of a sandal wood oil and turmeric based cream prevents radiodermatitis in head and neck cancer patients undergoing external beam radiotherapy: a pilot study. Br J Radiol, 2014; 87(1038):20130490.
Lo VermeJ, FuJ, AstaritaG, et al.The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol, 2005; 67(1):15–19.
40.
SimpsonELMM, IrvineADM, EichenfieldLFM, et al.Update on epidemiology, diagnosis, and disease course of atopic dermatitis. Semin Cutan Med Surg, 2016; 35(5 Suppl):S84–S88.
41.
EichenfieldLF, TomWL, ChamlinSL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol, 2014; 70(2):338–351.
42.
NuttenS. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab, 2015; 66(Suppl 1):8–16.
43.
BelsitoDV. Occupational contact dermatitis: etiology, prevalence, and resultant impairment/disability. J Am Acad Dermatol, 2005; 53(2):303–313.
LushniakBD. The epidemiology of occupational contact dermatitis. Dermatol Clin, 1995; 13(3):671–680.
46.
ParkinsonE, SkippP, AleksicM, et al.Proteomic analysis of the human skin proteome after in vivo treatment with sodium dodecyl sulphate. PLoS One, 2014; 9(5): e97772.
47.
KupczykP, ReichA, SzepietowskiJC. Cannabinoid system in the skin - a possible target for future therapies in dermatology. Exp Dermatol, 2009; 18(8):669–679.
48.
FacciL, Dal TosoR, RomanelloS, et al.Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci U S A, 1995; 92(8):3376–3380.
49.
BerdyshevEV, BoichotE, GermainN, et al.Influence of fatty acid ethanolamides and delta9-tetrahydrocannabinol on cytokine and arachidonate release by mononuclear cells. Eur J Pharmacol, 1997; 330(2–3):231–240.
50.
BerdyshevE, BoichotE, CorbelM, et al.Effects of cannabinoid receptor ligands on LPS-induced pulmonary inflammation in mice. Life Sci, 1998; 63(8):Pl125–129.
51.
JaggarSI, HasnieFS, SellaturayS, et al.The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain, 1998; 76(1–2):189–199.
52.
DerakhshanN, KazemiM. Cannabis for refractory psoriasis-high hopes for a novel treatment and a literature review. Curr Clin Pharmacol, 2016; 11(2):146–147.
53.
PetrosinoS, PuigdemontA, Della ValleMF, et al.Adelmidrol increases the endogenous concentrations of palmitoylethanolamide in canine keratinocytes and down-regulates an inflammatory reaction in an in vitro model of contact allergic dermatitis. Vet J, 2016; 207:85–91.
54.
OlahA, TothBI, BorbiroI, et al.Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. J Clin Invest, 2014; 124(9):3713–3724.
55.
LaumannA, LaiS, LuckyA, et al.The efficacy and safety of Mimyx cream in reducing the risk of relapse in Atopic Dermatitis. J Am Acad Dermatol, 2006; 54(3):AB80.
56.
SugawaraK, BiroT, TsurutaD, et al.Endocannabinoids limit excessive mast cell maturation and activation in human skin. J Allergy Clin Immunol, 2012; 129(3):726–738.e8.
57.
KendallAC, PilkingtonSM, SassanoG, et al.N-acyl ethanolamide and eicosanoid involvement in irritant dermatitis. Br J Dermatol, 2016; 175(1):163–171.
58.
NamG, JeongSK, ParkBM, et al.Selective cannabinoid receptor-1 agonists regulate mast cell activation in an oxazolone-induced atopic dermatitis model. Ann Dermatol, 2016; 28(1):22–29.
59.
AbramoF, CamporaL, AlbaneseF, et al.Increased levels of palmitoylethanolamide and other bioactive lipid mediators and enhanced local mast cell proliferation in canine atopic dermatitis. BMC Vet Res, 2014; 10:21.
